Verastem Inc
verastem.comVerastem Inc (NASDAQ: VSTM) is a commercial-stage oncology biopharmaceutical company that develops and sells targeted cancer therapies. Revenue is generated through product sales of AVMAPKI FAKZYNJA CO-PACK, distributed via specialty pharmacy and specialty distributor channels, with net revenue reduced by trade discounts, allowances, chargebacks, and third-party payer fees. Verastem became a public company on January 27, 2012, and is incorporated in Delaware. As of the fiscal year ended December 31, 2025, the company continued to incur operating losses, with cash used in operating activities of $137.5 million in FY2025 compared to $104.8 million in FY2024. Accumulated losses since inception reflect a pre-profitability stage despite active commercialization. The company has funded operations through equity offerings, convertible preferred stock, debt facilities, and at-the-market programs. No competitors are named in the available filing excerpts.
Products & Services
AVMAPKI FAKZYNJA CO-PACK: a co-packaged oncology product sold through specialty pharmacy and specialty distributor channels as of FY2025.
Revenue Model
Product revenue from sales of AVMAPKI FAKZYNJA CO-PACK to specialty pharmacy and specialty distributor customers, net of trade discounts, prompt-payment allowances, third-party payer chargebacks, and distribution service fees recorded as revenue reductions (FY2025, per 10-K filed 2026-03-04).
Customers & Markets
Specialty pharmacies and specialty distributors serve as direct customers. End market is oncology patients covered by Medicare, Medicaid, and third-party commercial payers. Reimbursement from government and commercial payers is material to product pricing and demand.
Financial Snapshot
Loading...
